Supplement-To-Drug Applications Look Like The Next Wave To Some Experts
This article was originally published in The Tan Sheet
Executive Summary
FDA's dietary supplement good manufacturing practices, while imposed to help assure safe nutritionals reach the market, are creating costs that could drive more firms to file new drug applications for natural products, according to a pair of regulatory experts
You may also be interested in...
Technical Hurdles, Commercial Limits Complicate Supplement-To-Drug Moves
Firms should investigate regulatory hurdles and gauge the commercial appeal of a finished product before moving dietary supplement ingredients into the pharmaceutical realm, say manufacturing and testing consultants
Fish Oil Firms Float Toxicology Work, Plot Media Blitz To Fight PCB Suit
Fish oil supplement manufacturers will rely on science and strategic public relations to counter a California lawsuit alleging high levels of undisclosed contaminants in their products
Dietary Supplements Blossom As Revenue Growth Ingredients For Big Pharma
Dwindling product pipelines are pushing pharmaceutical companies to look to dietary supplements for business opportunities, not only through product sales but also by using herbal substances to develop new drug ingredients